Gastrointestinal Amyloid Screening Study (GASS): is screening for amyloid in the gastrointestinal tract useful?

Click to increase image sizeClick to decrease image size

Acknowledgments

We would like to acknowledge the efforts of the remainder of the gastroenterologists who collaborated on this study including Drs. Matthew Allemang, Claire Beveridge, Scott Gabbard Andrew Grubic, Claire Jansson-Knodell and Taha Qazi.

Disclosure statement

Dr. Khedraki serves on the speaker bureau for Alnylam and Astra Zeneca. Dr. Cline has industry relationships with Evoke Pharmaceuticals, Kate Farms and ATMO Biosciences. Dr. Cohen serves on the advisory board and consultant for Abbvie, Takeda, TARGET RWE, speaker for Abbvie and educational grant from Pfizer. Dr. Reider has industry relationships with Adiso, Adnovate, Agomab, Allergan, AbbVie, Arena, Astra Zeneca, Boehringer-Ingelheim, Celgene/BMS, Celltrion, CDISC, Celsius, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Granite, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Landos, Jannsen, Koutif, Mestag, Metacrine, Mopac, Morphic, Organovo, Origo, Palisade, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Sanofi, Surmodics, Surrozen, Takeda, Techlab, Teva, Theravance, Thetis, UCB, Ysios, 89Bio. Dr. Hanna has served on advisory boards for Pfizer, Alnylam, Eidos, Ionis and Alexion Pharmaceuticals. All other authors have no relationships to disclose.

Additional information

Funding

This study at the Cleveland Clinic is supported by Dr. Hanna’s Term Chair for Amyloid Heart Disease.